Mubucho (Dasatinib)

Dasatinib, the active ingredient in Mubucho, is a tyrosine kinase inhibitor presented as an oral formulation for oral administration. It targets BCR‑ABL and Src family kinases, providing therapeutic benefit in chronic myeloid leukemia and Philadelphia‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Mubucho as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, oncology centres, transplant units and pharmacies worldwide with consistent quality and regulatory compliance.

Dasatinib is indicated for hematologic malignancies driven by the BCR‑ABL fusion protein and related tyrosine‑kinase pathways.

- Chronic myeloid leukemia (chronic phase): achieves cytogenetic and molecular remission by inhibiting leukemic cell proliferation. - Chronic myeloid leukemia (accelerated phase): reduces disease progression and improves hematologic response. - Chronic myeloid leukemia (blast phase): provides disease control when combined with other therapies. - Philadelphia‑positive acute lymphoblastic leukemia: induces remission by targeting BCR‑ABL‑positive blasts.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Myelosuppression (neutropenia, thrombocytopenia) - Fluid retention or peripheral edema - Nausea - Diarrhea

Serious or Rare Side Effects: - Pulmonary arterial hypertension - Severe hemorrhage - Cardiac dysfunction (e.g., left‑ventricular failure)

Careful monitoring is required before and during therapy.

- Blood counts: perform regular complete blood count monitoring. - Fluid status: assess for signs of edema or pleural effusion. - Cardiac function: evaluate baseline and periodic cardiac assessment. - Hepatic impairment: use with caution in patients with severe liver dysfunction. - Pregnancy: avoid use unless potential benefit justifies the risk; safety data are limited. - Store at room temperature: keep in the original container, protect from moisture.

Dasatinib may interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) - QT‑prolonging agents (e.g., sotalol, quinidine)

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (may reduce absorption) - Warfarin (potential alteration of INR)